Gossamer Bio, Inc. (GOSS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.18-0.17%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Stabilize or grow revenue: rev -19.7% vs -3%.
Gossamer Bio plans to submit a drug application by September 2026. The company started a share buyback program recently. New convertible notes help manage its capital. Revenue beat in Q1 shows some growth. These steps could help the company recover.
Gossamer Bio is still losing money and has volatile management. The stock fell 9% in one day recently. The company faces legal and financial challenges. Revenue growth is expected to decline 3% next year. These problems could hurt the turnaround.
The market expects about 3% revenue decline next year. Our fair value matches the Street median near $1. The price reflects high risks and weak growth. We differ by watching for a turnaround that is not yet proven.
Breaks if: Convertible notes fail to improve capital allocation
Strengthen balance sheet and extend debt maturity by exchanging existing convertible notes for new secured convertible notes and equity instruments.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making and has a volatile management track record, which adds to the uncertainty of its long-term thesis.
The market appears to price GOSS as relatively cheap compared to its peers, with an expectations gap suggesting that investors are not overly optimistic. The current valuation reflects a justified stance, but there is a low confidence in the underlying model.
Management's focus on submitting an NDA for seralutinib shows some promise, but revenue growth from collaborations has been declining. The high probability of an earnings miss in the near term adds to the uncertainty surrounding the company's performance.
The future of GOSS depends on management's ability to execute on key priorities, particularly the NDA submission and capital allocation. Additionally, market conditions, including the performance of sector bellwethers and overall economic indicators, will play a crucial role in shaping the company's trajectory.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. Gossamer Bio secured up to $250 million in funding. This gives the company more financial headroom for its operations. However, analysts are split on seralutinib's potential. This uncertainty threatens the clinical development outlook for the drug.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 3 disclosures including 2026-Q1 and two 2026-06 and 2026-08 press releases. The company exchanged approximately $181.1 million of $200 million outstanding notes for new notes and equity, reducing debt by about $115.9 million and extending maturity to 2030. This capital allocation priority is delivering with a strengthened balance sheet and extended debt maturity.
“We have taken steps to address our capital structure through a proposed exchange of our convertible notes.”
Breaks if: NDA submission delayed beyond September 2026
Prepare and submit a New Drug Application for seralutinib in pulmonary arterial hypertension by September 2026 following FDA Pre-NDA Type B meeting.
Stated as a priority in 2 distinct disclosures including 2026-Q1 and a later 2026-08-13 press release. Management expects to submit an NDA for seralutinib in PAH in September 2026 following a Pre-NDA Type B meeting. The FDA meeting minutes characterized statistical significance as review issues, supporting the planned submission. The trajectory is delivering as the company remains on track for the planned NDA submission.
“Subject to the outcomes of that meeting, we expect to submit an NDA for seralutinib in PAH in September of this year.”
Breaks if: Revenue growth falls below -3% next year
Breaks if: No buyback program announced or executed by mid-2026
Announce and potentially execute a share buyback program as part of capital allocation strategy.
Newly stated in mid-2026. Management announced a share buyback program concurrent with the convertible note exchange. No financial data on buyback execution or magnitude is available, so the trajectory is pending further disclosure.
In the next 1 to 3 years, GOSS faces significant challenges but also has potential catalysts that could influence its performance. Not investment advice.